Anthracycline-based regimens with cisplatin have been commonly used for inoperable and relapsed thymoma. However, little information is available regarding the usefulness of salvage chemotherapy. Here, we describe a case of invasive thymoma associated with myasthenia gravis that showed a marked response to third-line chemotherapy, with single-agent amrubicin, a synthetic anthracycline analog and potent deoxyribonucleic acid topoisomerase II inhibitor. Amrubicin appears to have significant activity against invasive thymoma.
CITATION STYLE
Fukushima, T., Gomi, D., Kobayashi, T., Sekiguchi, N., Sakamoto, A., Sasaki, S., & Koizumi, T. (2014). Successful salvage chemotherapy with amrubicin for invasive thymoma associated with myasthenia gravis. Japanese Journal of Clinical Oncology, 44(11), 1120–1122. https://doi.org/10.1093/jjco/hyu136
Mendeley helps you to discover research relevant for your work.